|
|
|
|
|
|
By Andrew Knappenberger, Ph.D., Somatek | Here's a case for the biotech hybrid model, one that relies on a crack team of internal core talent complemented by broad reliance on external vendors. Consider how to optimize resources to drive your drug development program toward success. | |
|
|
|
| Next-Generation CRISPR Approaches | White Paper | Aldevron | By providing essential components like nucleases, gRNAs, and HDR templates, a reliable CDMO facilitates a seamless transition from discovery research to clinical trials and beyond. |
|
|
|
| Built‑In Quality For Audit‑Ready Manufacturing | Article | By Melodie Bryce, Kincell Bio | Pre-approval success depends on integrating traceability and contamination control into daily workflows. Avoid regulatory delays by ensuring your manufacturing process is inherently compliant. |
|
|
|
| Enhancing Stability With Frozen Starting Materials | Article | Cryoport Systems | Fresh starting materials introduce variability and fragility, but frozen inputs create predictable, scalable workflows that improve consistency and support smoother early‑phase development. |
|
|
| A CRDO Method To Faster Biologic Development | Article | Dr. Ivonne Stelzl and Dr. Matthias Lucke, Coriolis Pharma | A science‑driven CRDO model accelerates biologic development by combining expert formulation, analytics, and partnerships to reduce risk and improve outcomes. Consider the benefits of a collaborative approach. |
|
|
|
| Streamline AAV-Based Gene Therapies With Off-The-Shelf Plasmids | White Paper | By George Buchman and Bhargavi Kondragunta, Catalent | Standardized plasmids and streamlined platform processes can significantly accelerate viral vector development, improve consistency, and support scalable, high-quality gene therapy manufacturing. |
|
|
|
|
|
|
|
| Connect With Cell & Gene: |
|
|
|
